Sharekhan's research report on Solara Active Pharma Sciences
The Board of Solara has approved the amalgamation of Aurore Life Sciences, Empyrean Life Sciences, and Hydra Active Pharma Sciences with Solara. The merger opens up substantial growth opportunities for Solara going ahead. The combined entity would be a pure play API company of scale, with a strong presence in regulated markets and emerging markets, having a broad product portfolio, robust operations infrastructure, and excellent R&D capabilities; and it would strengthen the CRAMS business of Solara with clear synergies to further accelerate growth.
Outlook
We retain our Buy recommendation on the stock with a revised PT of Rs. 1,730.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More